arrow
S

Shampa Das

University of Liverpool
H指数:25
被引数:2,429

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Innovative roadmaps for sustainable antimicrobial resistance interventions

创新的道路图用于可持续的抗菌素耐药性干预措施

2026-10-140
PRE
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions

NOSO-502的药效学指标幅度:病原体清除、耐药性出现及人体剂量预测

2026-04-010
PRE
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections (vol 15, 8202, 2024)

BWC0977,一种广谱抗菌临床候选药物,用于治疗多药耐药感染(卷15,8202,2024)

2025-02-280
OA
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections (vol 15, 8202, 2024)

BWC0977,一种用于治疗多药耐药感染的广谱抗菌临床候选药物(卷15,8202,2024)

2025-01-130
OA
Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA
2024-10-162
PRE
Acinetobacter baumannii transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-Acinetobacter drug development and AMR preparedness

表达对美罗培南具有耐药性的oxacillinase和金属 β-内酰胺酶的鲍曼不动杆菌转化体: 抗不动杆菌药物开发和AMR准备的新工具

2024-10-080
PRE
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
2024-09-180
OAAI
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
2022-09-302
OAAI
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance
2021-06-1719
OA